Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

A simple phone call may help millions with diabetes manage insulin — a trial puts it to the test

NCT ID NCT07729501

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Sep 16, 2026 · Updated 4 times

Summary

This trial tests whether a multilingual interactive voice response (IVR) system can help adults with type 2 diabetes and low health literacy adjust their insulin doses. Participants use a feature phone to report blood sugar levels and receive algorithm-guided dose recommendations, reviewed by clinical staff. The study compares this approach to standard clinic-based insulin titration over 12 weeks, measuring changes in blood sugar control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
multilingual interactive voice response (IVR) system for insulin dose adjustment
What this could lead to
If it works, this could offer a simple, phone-based way for people with low health literacy to manage insulin dosing at home, improving blood sugar control.
What could go wrong
The trial is small (220 participants) and short (12 weeks), so results may not apply to broader populations or longer-term outcomes. The system still requires human review, so it is not fully automated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Diagnosed with type 2 diabetes mellitus. * Currently receiving basal insulin or considered by the treating clinician to require initiation or adjustment of basal insulin. * Glycemic control considered inadequate and requiring basal insulin titration according to the study protocol. * Low health literacy as determined using the study-approved screening method. * Able to communicate in one of the languages supported by the study intervention. * Has access to a functioning feature phone or mobile telephone and is able to receive automated voice calls. * Able and willing to perform fasting blood glucose monitoring according to the study procedures. * Willing and able to provide informed consent. * Willing to comply with study procedures and complete the 12-week follow-up. Exclusion Criteria: * Type 1 diabetes mellitus, gestational diabetes, or another specific form of diabetes other than type 2 diabetes mellitus. * Pregnancy, current breastfeeding, or planned pregnancy during the study period. * Current use of an insulin pump. * Severe hypoglycemia requiring assistance from another person within the period specified in the protocol before enrollment. * Recurrent hypoglycemia or another clinical condition that, in the investigator's judgment, makes protocol-directed insulin titration unsafe. * Acute metabolic decompensation, including diabetic ketoacidosis or hyperosmolar hyperglycemic state, at screening or within the period specified in the protocol. * Severe renal, hepatic, cardiac, psychiatric, cognitive, hearing, or other medical impairment that would prevent safe participation or completion of the voice-call intervention. * Inability to understand or respond to the study's supported voice-call languages. * Inability to use the telephone or glucose-monitoring procedures, with or without assistance permitted by the protocol. * Current participation in another interventional clinical trial that could interfere with the study outcomes. * Any other condition that, in the investigator's judgment, would make participation unsafe or compromise adherence to the study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperglycemia due to type 2 diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shifa Hospital

    Lahore, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.